Mirabegron Zentiva

Mirabegron, the active ingredient in Mirabegron Zentiva, is a beta‑3 adrenergic receptor agonist presented as an oral tablet for oral use. Approved in the European Union, it treats overactive bladder symptoms—including urgency, frequency and urge urinary incontinence—in adult patients.

GNH USA supplies Mirabegron Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to hospitals, pharmacies and clinics worldwide under strict quality standards. The company supports global procurement, regulatory compliance and reliable logistics for institutional buyers, ensuring timely delivery and product integrity.

Mirabegron acts on the beta‑3 adrenergic pathway to improve bladder storage function in overactive bladder conditions.

- Overactive bladder: improves bladder capacity and reduces urgency episodes. - Urinary urgency: decreases the frequency of sudden urges to void. - Urinary frequency: lowers the number of daytime voids. - Urge urinary incontinence: reduces involuntary leakage episodes.

Mirabegron may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Hypertension: mild increase in blood pressure. - Headache: transient head pain. - Nasopharyngitis: symptoms of upper respiratory tract infection. - Urinary retention: difficulty emptying the bladder. - Dry mouth: reduced salivation.

Serious or Rare Side Effects: - Severe hypertension: marked elevation of blood pressure requiring medical attention. - Acute urinary retention leading to bladder outlet obstruction. - Allergic reactions: rash, swelling, or anaphylaxis.

Before initiating Mirabegron therapy, clinicians should consider several safety precautions.

- Assess cardiovascular status: measure baseline blood pressure and monitor regularly during treatment. - Review renal function: adjust use in patients with severe renal impairment as recommended. - Evaluate for urinary retention risk: avoid in individuals with known bladder outlet obstruction. - Consider drug interactions: avoid concomitant use with strong CYP2D6 inhibitors without dose adjustment. - Pregnancy and lactation: use only if potential benefit justifies potential risk, as safety data are limited. - Store below 25°C: keep in the original packaging, protect from moisture and heat.

Mirabegron can affect the pharmacokinetics of several medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Strong CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): may increase mirabegron plasma concentrations. - Antihypertensive agents (e.g., beta‑blockers, ACE inhibitors): additive blood‑pressure‑lowering effect may require monitoring.

Moderate Interactions (Monitor Closely): - Diuretics: may alter fluid balance and affect blood pressure control. - Nitrates: combined use can enhance hypotensive response. - Other beta‑3 agonists: additive pharmacodynamic effect may increase risk of urinary retention.